Detalles de la búsqueda
1.
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.
BMC Cancer
; 20(1): 523, 2020 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32503469
Resultados
1 -
1
de 1
1
Próxima >
>>